Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

Journal of Clinical Investigation

Volumn 123, Issue 5, 2013, Pages 2155-2168

  Abel, Ethan V ^a   Basile, Kevin J ^a   Kugel III, Curtis H ^a   Witkiewicz, Agnieszka K ^a   Le, Kaitlyn ^a   Amaravadi, Ravi K ^b   Karakousis, Giorgos C ^c   Xu, Xiaowei ^c   Xu, Wei ^b   Schuchter, Lynn M ^b   Lee, Jason B ^a   Ertel, Adam ^a   Fortina, Paolo ^a   Aplin, Andrew E ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BETA GALACTOSIDASE; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GEFITINIB; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXD3; UNCLASSIFIED DRUG; VEMURAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER RECURRENCE; CANCER SURVIVAL; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VIVO STUDY; LONG TERM CARE; LUNG CANCER; MELANOMA; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION;

CELL SURVIVAL; ENZYME INHIBITORS; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; MAP KINASE KINASE KINASES; MELANOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; QUINAZOLINES; RAF KINASES; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; SULFONAMIDES; TRANSCRIPTION, GENETIC;

EID: 84877124454     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI65780     Document Type: Article

References (57)

1. Satyamoorthy K, et al. Constitutive mitogenactivated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res. 2003;63(4):756-759.
2. Reifenberger J, et al. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer. 2004;109(3):377-384.
3. Davies H, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
4. Sumimoto H, et al. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene. 2004;23(36):6031-6039.
5. Wellbrock C, Rana S, Paterson H, Pickersgill H, imp T, Marais R. Oncogenic BRAF reguoma proliferation through the lineage torMITF.PLoSOne. 2008;3(7):e2734.
6. Wang YF, Jiang CC, Kiejda KA, Gillespie S, Zhang XD, Hersey P. Apoptosis induction in human melanoma cells by inhibition of MEK is caspaseindependent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin Cancer Res. 2007;13(16):4934-4942.
7. Boisvert-Adamo K, Aplin AE. B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis. Oncogene. 2006;25(35):4848-4856.
8. Bhatt KV, Spofford LS, Aram G, McMullen M. Pumiglia K, Aplin AE. Adhesion control of cyclin D1 and p27Kip 1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene. 2005;24(21):3459-3471.
9. Solit DB, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439(7074):358-362.
10. Chapman PB, et al. Improved survival with vemu-rafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
11. Smalley KSM, et al. Increased cyclin Dl expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther. 2008;7(9):2876-2883.
12. Montagut C, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008;68(12):4853-4861.
13. Johannessen CM, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468(7326):968-972.
14. Nazarian R, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973-977.
15. Villanueva J, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18(6):683-695.
16. Spofford LS, Abel EV, Boisvert-Adamo K, Aplin AE. Cyclin D3 expression in melanoma cells is regulated by adhesion-dependent phosphatidylinositol 3-kinase signaling and contributes to Gl-S progression. J Biol Chem. 2006;281(35):25644-25651.
17. Paraiso KHT, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011;71(7):2750-2760.
18. Shao Y, Aplin AE. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. CancerRes. 2010;70(16):6670-6681.
19. Poulikakos PI, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480(7377):387-390.
20. Emery CM, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. ProcNatlAcad Sei USA. 2009;106(48):20411-20416.
21. Wagle N, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085-3096.
22. Abel EV, Aplin AE. FOXD3 is a mutant B-RAF-regulated inhibitor of Gl-S progression in melanoma cells. CancerRes. 2010;70(7):2891-2900.
23. Basile KJ, Abel EV, Aplin AE. Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene. 2012;31(19):2471-2479.
24. Sergina NV, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445(7126):437-441.
25. EngelmanJA, et al. MET amplification leads to gefi-tinib resistance in lung cancer by activating ERBB3 signaling. Samce. 2007;316(5827):1039-1043.
26. Chakrabarty A, Sanchez V, Kuba MG, Rinehart C, Arteaga CL. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. ProcNatlAcad Sei US A. 2011;109(8):5021-5026.
27. Garrett JT, et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. ProcNatlAcad Sei USA. 2011;108(12):5021-5026.
28. Reschke M, et al. HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res. 2008;14(16):5188-5197.
29. Buac K, Xu M, Cronin J, Weeraratna AT, Hewitt SM, Pavan WJ. NRG1/ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation. Pigment Cell Melanoma Res. 2009;22(6):773-784.
30. Prasad M, et al. SOX10 directly modulates ERBB3 transcription via an intronic neural crest enhancer. BMC Dev Biol. 2011;11:40.
31. Ni M, et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell. 2011;20(1):119-131.
32. Rivera-Feliciano J, et al. Development of heart valves requires Gata4 expression in endothelial-derived cells. Development. 2006;133(18):3607-3618.
33. Ahn SH, Kim M, Buratowski S. Phosphorylation of serine 2 within the RNA polymerase II C-terminal domain couples transcription and 3' end processing. Mol Cell. 2004; 13(1):67-76.
34. Phatnani HP, Greenleaf AL. Phosphorylation and functions of the RNA polymerase II CTD. Genes Dev. 2006;20(21):2922-2936.
35. Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin BJ, Yarden Y. Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. JBiolChem. 1996;271(32):19029-19032.
36. Campbell MR, Amin D, Moasser MM. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin CancerRes. 2010;16(5):1373-1383.
37. Flaherty KT, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Eng J Med. 2012;367(18):1694-1703.
38. Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther. 2008;15(7):413-448.
39. Prickett TD, et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet. 2009;41(10):1127-1132.
40. Qiu C, et al. Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure. 2008;16(3):46 0-467.
41. XuJ, et al. Transcriptional competence and the active marking of tissue-specific enhancers by defined transcription factors in embryonic and induced pluripotent stem cells. Genes Dev. 2009;23(24):282 4-2838.
42. Shi H, Kong X, Ribas A, Lo RS. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res. 2011;71(15):5067-5074.
43. Xing F, et al. Concurrent loss of the PTEN and RBI tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF. Oncogene. 2012;31(4):446-457.
44. Deng W, Yennu-Nanda VG, Scott A, Chen G. Woodman SE, Davies MA. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res. 2011;25(2):248-258.
45. Gopal YNV, et al. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res. 2010;70(21):8736-8747
46. Choi W, et al. The fibroblast-derived paracrine factor neuregulin-1 has a novel role in regulating the constitutive color and melanocyte function in human skin. J Cell Sci. 2010;123(pt 18):3102-3111.
47. Prahallad A, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387): 100-103.
48. Nelson MH, Dolder CR. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother. 2006;40(2):261-269.
49. Burris HA 3rd. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist. 2004;9(suppl3):10-15.
50. Schoeberl B, et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. CancerRes. 2010;70(6):2485-2494.
51. Schoeberl B, et al. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PBKaxis. Sci Sig. 2009;2(77):ra31.
52. Storey JD. A direct approach to false discovery rates. JRStatSocSerB StatMethodol. 2002;64(pt 3):479-498.
53. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucl Acids Res. 2001;29(9):e45.
54. Feng J, Liu T, Zhang Y. Using MACS to identify peaks from ChlP-Seq data. Curr Protoc Bioin form atics. 2011;chapter2:unit2.14.
55. Zhang Y, et al. Model-based analysis of ChlP-Seq (MACS). Genome Biol. 2008;9(9):R137.
56. Shin H, Liu T, Manrai AK, Liu XS. CEAS: cis-regulatory element annotation system. Bioinformatics. 2009;25(19):2605-2606.
57. Robinson JT, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24-26.